cfDNA Assay Prospective Observational Validation for Early Cancer Detection and Minimal Residual Disease

Abroad (travel likely)Recruiting

Conditions

Brain Cancer · Breast Cancer · Bladder Cancer · Cervical Cancer · Colorectal Cancer · Endometrial Cancer · Esophageal Cancer · Stomach Cancer · Head and Neck Cancer · Hepatobiliary Cancer · Leukemia · Lung Cancer · Lymphoma · Multiple Myeloma · Ovarian Cancer · Pancreatic Cancer · Prostate Cancer · Renal Cancer · Sarcoma · Thyroid Cancer

Simple summaryAI-assisted

This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.

Locations
  • City of Hope, Duarte, California, United States

    Contact: Study coordinator (Xiao-Yu Xia) · xxia@coh.org · 626-218-0630
    Contact: Principal Investigator (Gregory Idos, MD)
  • Miami Cancer Institute, Miami, Florida, United States

    Contact: Study coordinator (Belkys Salinas) · Belkys.salinas@baptisthealth.net
    Contact: Principal Investigator (Manmeet Ahluwalia, MD)
  • North Georgia Health System, Gainesville, Georgia, United States

    Contact: Study coordinator (Trena Davis) · Trena.Davis@nghs.com
    Contact: Principal Investigator (Charles Nash, MD)
  • Baptist Floyd, New Albany, Indiana, United States

    Contact: Study coordinator (Tasha Dodson) · tasha.dodson@bhsi.com
    Contact: Principal Investigator (Amitoj Gill, MD)
  • Baptist Corbin, Corbin, Kentucky, United States

    Contact: Study coordinator (Janie Platt) · Janie.Platt@bhsi.com
    Contact: Principal Investigator (Abigail Byrnes, MD)
  • Baptist Hardin, Elizabethtown, Kentucky, United States

    Contact: Study coordinator (Amy Steward) · amy.steward@bhsi.com
    Contact: Principal Investigator (Christopher Burkeen, MD)
  • Baptist Lexington, Lexington, Kentucky, United States

    Contact: Study coordinator (Janie Platt) · Janie.Platt@bhsi.com
    Contact: Principal Investigator (Arvinda Padmanabhan, MD)
  • Baptist Paducah, Paducah, Kentucky, United States

  • Allina Health Cancer Institute, Minneapolis, Minnesota, United States

    Contact: Study coordinator (Jonathon Alexander) · jonathan.alexander@allina.com · 612-863-8625
    Contact: Study coordinator (Jennie Schletty) · jennie.schletty@allina.com · 612-863-8625
    Contact: Principal Investigator (Joleen Hubbard, MD)
  • Mayo Clinic, Rochester, Minnesota, United States

    Contact: Study coordinator (Angela R Emanuel) · emanuel.angela@mayo.edu
    Contact: Principal Investigator (Lisa A Boardman, MD)
  • Cleveland Clinic, Cleveland, Ohio, United States

    Contact: Study coordinator (Mofetoluwa Oluwasanmi) · oluwasm@ccf.org · 216-444-0843
    Contact: Principal Investigator (Peter Mazzone, MD, MPH)
  • Oregon Health Sciences University, Portland, Oregon, United States

    Contact: Study coordinator (Diana Potts) · pottsd@ohsu.edu
    Contact: Principal Investigator (Nima Nabavizadeh, MD)
  • Medical University of South Carolina, Charleston, South Carolina, United States

    Contact: Study coordinator (Michael Balassone) · balassom@musc.edu · 843-792-6696
    Contact: Study coordinator (Andrew M Chen) · chenand@musc.edu
    Contact: Principal Investigator (Gerard Silvestri, MD)
  • McLeod Health, Florence, South Carolina, United States

    Contact: Study coordinator (Betsy Harris) · bharris@mcleodhealth.org
    Contact: Principal Investigator (Virginia Clyburn-Ipock, MD)
  • Baptist (BHMCC), Memphis, Tennessee, United States

    Contact: Study coordinator (Tracy Stewart) · tracy.stewart2@bmhcc.org
    Contact: Principal Investigator (Philip Lammers, MD)
  • Vanderbilt-Ingram Cancer Center, Nashville, Tennessee, United States

    Contact: Study coordinator (Anna Dumont) · anna.dumont@vumc.org
    Contact: Principal Investigator (Brian Rini, MD)
  • Elligo Health Research, Inc., Austin, Texas, United States

    Contact: Study coordinator (Cynthia Currasco) · cynthia.currasco@elligodirect.com
    Contact: Principal Investigator (Faith Holmes, MD)
Study leads
  • Brian Rini, MD

    Principal Investigator

    Vanderbilt-Ingram Cancer Center